Search the Newsreel

CareDx (CDNA) insider Peter Maag files to sell 7,000 NASDAQ-listed shares

CareDx, Inc. insider Peter Maag has filed a notice to sell 7,000 shares of common stock, valued at $328,237.70, through Morgan Stanley Smith Barney LLC. These shares originated from restricted stock awards in late 2023 and early 2024. The filing also disclosed recent sales …

Baron Discovery Fund Gains from Strategic Accumulation of CareDx (CDNA)

The Baron Discovery Fund increased its position in CareDx (CDNA) after shares declined in Q3 2025 due to a draft local coverage decision by CMS that threatened reimbursement for its diagnostic tests. The fund believed the stock was undervalued at $11-12, representing a worst-case …

CareDx (CDNA) Trades 68% Above Fair Value Following Strong Q2 And Raised Guidance

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 7, 2026

CareDx, Inc. announced inducement grants of restricted stock units (RSUs) to 35 new employees as a material incentive for their employment. A total of 97,090 shares of common stock were awarded, with most RSUs vesting over four years and one employee's RSUs vesting 100% …

This Insider Has Just Sold Shares In CareDx

CareDx's Independent Chairman, Michael Goldberg, recently sold US$2.1m worth of shares, reducing his total holding by 24%. While this is the largest insider sale in the past year, the shares were sold at a price close to the current market value. Despite no insider …

State Street (CDNA holder) discloses 2.47M CareDx shares under shared control

State Street Corporation has reported a beneficial ownership of 2,468,858 shares of CareDx, Inc. common stock, which represents 4.8% of the class, according to a Schedule 13G SEC filing. All voting and dispositive authority for these shares is shared through affiliated investment adviser entities. …

CareDx (CDNA): Neil Gagnon and Gagnon entities report 4.4% ownership stake

Neil Gagnon and his affiliated entities, Gagnon Securities LLC and Gagnon Advisors, LLC, have reported a collective ownership stake of 4.4% in CareDx, Inc. (CDNA) common stock through a SCHEDULE 13G/A SEC filing. Neil Gagnon individually beneficially owns 2,293,464 shares (4.4%), while Gagnon Securities …

CareDx (NASDAQ: CDNA) insider Peter Maag plans 27,332-share stock sale after option exercise

CareDx, Inc. insider Peter Maag has filed to sell 27,332 shares of Common Stock, which are tied to a stock option exercise dated August 7, 2026. The sale will be executed on NASDAQ through Morgan Stanley Smith Barney LLC’s Executive Financial Services program. The …

CareDx Inc (CDNA) Stock News Today

Statutory Earnings May Not Be The Best Way To Understand CareDx's (NASDAQ:CDNA) True Position

CareDx's recent strong earnings report, while positive on the surface, may not fully reflect the company's underlying financial health. The analysis highlights a high accrual ratio of 0.28, indicating that free cash flow significantly lagged statutory profit, partly due to a US$109m boost from …

Janus Henderson Group PLC Has $5.50 Million Stock Position in CareDx, Inc. $CDNA

Janus Henderson Group PLC has increased its stake in CareDx, Inc. (NASDAQ:CDNA) by 10.1% to 316,519 shares, valued at approximately $5.5 million. This comes as CareDx reported stronger-than-expected quarterly earnings with $0.37 EPS and revenue of $131.95 million, a 52.2% year-over-year increase. Despite a …

CareDx (NASDAQ:CDNA) Is Posting Healthy Earnings, But It Is Not All Good News

CareDx, Inc. (CDNA) Stock Analysis: Strong Revenue Growth and Investor Optimism Signal Potential Upside

CareDx, Inc. (CDNA) insider sells 2,688 shares under trading plan

CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack sold 2,688 shares of common stock on August 5, 2026, under a Rule 10b5-1 trading plan established in September 2025. The sales were executed in two tranches at weighted average prices of $46.1492 and $46.75 …

Dimensional Fund Advisors LP Has $25.38 Million Stock Position in CareDx, Inc. $CDNA

Dimensional Fund Advisors LP significantly increased its stake in CareDx, Inc. by 11.6% in the first quarter, now holding 1.46 million shares valued at $25.38 million. This comes as CareDx reported stronger-than-expected quarterly earnings and revenue. Despite mixed analyst ratings and recent insider stock …

CareDx, Inc. (CDNA) director sells 16,000 shares in planned trade

CareDx, Inc. director Christine Cournoyer sold 16,000 shares of common stock on August 4, 2026, under a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $46.9358 per share, ranging from $46.25 to $47.2250, leaving her with 42,943 shares. …

CareDx, Inc. SEC Filing (Aug 5, 2026)

This article details a CareDx, Inc. (CDNA) SEC Filing on Form 144, dated August 5, 2026. The filing indicates a proposed sale of 20,000 shares of common stock by an individual who acquired them as compensation for past services in 2015, with an aggregate …

Planned 46,963-share sale reported by CDNA insider (CDNA)

A Form 144 notice for CareDx, Inc. (CDNA) indicates a proposed sale of up to 46,963 shares of common stock, valued at $2,178,945.34 as of August 5, 2026, through Morgan Stanley Smith Barney LLC. These shares originate from restricted stock grants and a stock …

Price to sales forward of CareDx, Inc. – LS:A118WG

This article provides financial information for CareDx, Inc. (A118WG) from TradingView, focusing on its price to sales forward metric. It indicates that no trades were recorded and the market was closed. The content is primarily a data page with various links to other financial …

Why CareDx (CDNA) Is Up 33.8% After Strong Q2 Profit, Higher 2026 Outlook And ESOP Shelf

CareDx reported strong Q2 2026 results with significant revenue and net income increases, leading to a 33.8% stock surge. The company raised its full-year 2026 revenue outlook to US$490 million–US$500 million and filed an US$80.30 million shelf registration for an employee stock ownership plan. …

CareDx climbs another 9% after guidance raise, sets new 52-week high (CDNA:NASDAQ)

CareDx (CDNA) shares rallied over 9%, extending a previous 15% surge, after the company raised its full-year revenue guidance and reported strong second-quarter results. The precision medicine diagnostics company, focused on transplant patients, reached a new 52-week high. Key drivers include testing services segment …

CareDx Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against CareDx Inc. (NASDAQ: CDNA) and reminds investors of the July 22, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that CareDx engaged in improper schemes …

CareDx (CDNA) Following Raised Guidance And Profit Swing, Does The Stock Look Fully Valued

Key facts: CareDx (CDNA) raises 2026 revenue guide; grants 15,822 RSUs

CareDx (CDNA) Stock Jumps As Profitability Recasts The Growth Story

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx, Inc. (Nasdaq: CDNA) has announced inducement grants of 15,822 restricted stock units (RSUs) to James McNally, their newly appointed Executive Advisor. These RSUs were granted under the Company's 2025 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are …

CareDx: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for CareDx. Unfortunately, the content of the article itself is missing, preventing a detailed summary of the financial performance or key highlights.

CareDx (NASDAQ:CDNA) Announces Earnings Results, Beats Estimates By $0.15 EPS

CareDx (NASDAQ:CDNA) Sets New 1-Year High After Strong Earnings

CareDx Announces Second Quarter 2026 Financial Results

CareDx, Inc. reported strong second-quarter 2026 financial results, with a 52% year-over-year revenue increase to $132 million and GAAP net income of $111 million. The company raised its full-year 2026 revenue guidance to $490 million to $500 million and adjusted EBITDA guidance to $66 …

CDNA Looks 77.9% Overvalued on GF Value™ Amid Revenue Upgrade

Earnings Flash (CDNA) CareDx, Inc. Reports Q2 Revenue $131.9M, vs. FactSet Est of $113.8M

CareDx, Inc. (CDNA) reported Q2 revenue of $131.9 million, surpassing the FactSet estimate of $113.8 million. The company also announced adjusted EPS of $0.37 per share, significantly higher than the FactSet estimate of $0.23 per share. These financial results indicate a strong performance for …

CareDx, Inc. (CDNA) Q2 2026 Earnings

CareDx, Inc. (CDNA) reported impressive Q2 2026 earnings, significantly beating EPS and revenue expectations. The company saw a 59.5% beat on EPS with $0.37 against an estimated $0.23, and revenue reached $132 million, surpassing the $114 million estimate by 15.7%. This strong performance was …